The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.

Claims

8 · 1 independent · depth 4

8 granted claims

›1.independentAn immunoconjugate comprising an anti-ErbB2 antibody conjugated to a maytansinoid, wherein the antibody is huMAb4D5-8.+7

›2.↳ 1The immunoconjugate of claim 1, wherein the maytansinoid is DM1 having the structure:d2+2

›3.↳ 1The immunoconjugate of claim 1, wherein the immunoconjugate comprises from 3 to 5 maytansinoid molecules per antibody molecule.d2

›4.↳ 1The immunoconjugate of claim 1, wherein the antibody and the maytansinoid are conjugated by a chemical linker selected from N-succinimidyl-3-(2-pyridy…d2+1

›5.↳ 1multiple · 1, 2, 3, 4A pharmaceutical composition comprising an immunoconjugate of any of claims 1 to 4, and a pharmaceutically acceptable carrier.d2

Classifications

3 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07K16/00

USPC · US Patent Classification

530/387.1424/130.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

4.1 y

1,499 days filing → grant

Office actions

non-final + final

Responses

2 RCE

Interviews

examiner interview summaries

Examiner

Laura B Goddard

art unit 1643 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 340 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

5 Oct 2000

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 60238327	5 Oct 2000
related publication	US 20080226659 A1	18 Sep 2008

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.